Alternate Day Buprenorphine Administration, Phase X - 15
Primary Purpose
Opioid-Related Disorders
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Buprenorphine
Sponsored by
About this trial
This is an interventional treatment trial for Opioid-Related Disorders
Eligibility Criteria
Please contact site for information.
Sites / Locations
- Treatment Research Center
Outcomes
Primary Outcome Measures
Opioid withdrawal
Subjective dose estimate
Drug effect characteristics: ARCI
Money choice
Secondary Outcome Measures
Full Information
NCT ID
NCT00000233
First Posted
September 20, 1999
Last Updated
August 16, 2005
Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
University of Vermont
1. Study Identification
Unique Protocol Identification Number
NCT00000233
Brief Title
Alternate Day Buprenorphine Administration, Phase X - 15
Official Title
Alternate Day Buprenorphine Administration, Phase X
Study Type
Interventional
2. Study Status
Record Verification Date
September 1995
Overall Recruitment Status
Completed
Study Start Date
May 1993 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
University of Vermont
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid-Related Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Enrollment
0 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Buprenorphine
Primary Outcome Measure Information:
Title
Opioid withdrawal
Title
Subjective dose estimate
Title
Drug effect characteristics: ARCI
Title
Money choice
10. Eligibility
Sex
All
Minimum Age & Unit of Time
34 Years
Maximum Age & Unit of Time
51 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Please contact site for information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Warren Bickel, Ph.D.
Organizational Affiliation
University of Vermont
Official's Role
Principal Investigator
Facility Information:
Facility Name
Treatment Research Center
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
12. IPD Sharing Statement
Citations:
Citation
Petry, Bickel (in press) Buprenorphine self-administration in buprenorphine-maintained, opioid-dependent outpatients: Effects of an alternate reinforcer. Psychopharmacology. Petry, Bickel (in press) Buprenorphine self-administration in buprenorphine-maintained, opioid-dependent outpatients: Effects of an alternate reinforcer. Psychopharmacology
Results Reference
background
PubMed Identifier
35366570
Citation
Antoniotti C, Germani MM, Rossini D, Lonardi S, Pietrantonio F, Santini D, Marmorino F, Allegrini G, Daniel F, Raimondi A, Borelli B, Zaniboni A, Conca V, Abraham J, Spetzler D, Maiello E, Boccaccino A, Passardi A, Giordano M, Tamburini E, Korn MW, Masi G, Cremolini C. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. Eur J Cancer. 2022 May;167:23-31. doi: 10.1016/j.ejca.2022.02.031. Epub 2022 Mar 30.
Results Reference
derived
Learn more about this trial
Alternate Day Buprenorphine Administration, Phase X - 15
We'll reach out to this number within 24 hrs